Central Pharmaceutical Joint Stock Company No3

HNX:DP3 Stock Report

Market Cap: ₫1.2t

Central Pharmaceutical No3 Past Earnings Performance

Past criteria checks 5/6

Central Pharmaceutical No3 has been growing earnings at an average annual rate of 8.3%, while the Pharmaceuticals industry saw earnings growing at 8.3% annually. Revenues have been growing at an average rate of 1.1% per year. Central Pharmaceutical No3's return on equity is 26.6%, and it has net margins of 30.2%.

Key information

8.3%

Earnings growth rate

7.9%

EPS growth rate

Pharmaceuticals Industry Growth13.0%
Revenue growth rate1.1%
Return on equity26.6%
Net Margin30.2%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Central Pharmaceutical No3 makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

HNX:DP3 Revenue, expenses and earnings (VND Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 24395,207119,189134,6160
31 Mar 24393,686123,070133,9050
31 Dec 23409,731125,263144,6180
30 Sep 23437,247115,462169,1150
30 Jun 23454,355112,885182,6540
31 Mar 23478,070110,902203,0100
31 Dec 22485,074108,824208,7170
30 Sep 22466,732100,148208,8130
30 Jun 22439,43297,217197,1980
31 Mar 22410,10698,580164,3880
31 Dec 21381,07794,305151,4910
30 Sep 21377,540100,467145,0370
30 Jun 21384,213106,614142,3690
31 Mar 21381,982109,143139,2420
31 Dec 20395,721114,061140,3830
30 Sep 20390,30879,192170,3410
30 Jun 20414,64184,092176,9590
31 Mar 20417,25284,281161,3530
31 Dec 19411,43382,804159,9120
30 Sep 19422,77678,546171,4280
30 Jun 19433,39678,929172,0160
31 Mar 19451,12582,658185,4950
31 Dec 18471,50380,071194,9040
30 Sep 18439,46192,382156,6190
31 Dec 17328,14138,335138,5890
30 Sep 17321,38330,929138,8910
31 Dec 16237,63422,50389,1650
30 Sep 16224,75020,74883,1890
31 Dec 15212,09816,22076,0320
30 Sep 15198,8748,69569,0410
30 Jun 15191,6137,99662,0610
31 Mar 15187,9559,84359,0810
31 Dec 14184,29611,69056,1020

Quality Earnings: DP3 has high quality earnings.

Growing Profit Margin: DP3's current net profit margins (30.2%) are higher than last year (24.8%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: DP3's earnings have grown by 8.3% per year over the past 5 years.

Accelerating Growth: DP3's earnings growth over the past year (5.6%) is below its 5-year average (8.3% per year).

Earnings vs Industry: DP3 earnings growth over the past year (5.6%) exceeded the Pharmaceuticals industry -13%.

Return on Equity

High ROE: DP3's Return on Equity (26.6%) is considered high.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 22:08
End of Day Share Price 2025/01/10 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Central Pharmaceutical Joint Stock Company No3 is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution